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Background: Cardiopulmonary exercise test (CPT) has a prominent value in assessing clinical severity in
chronic heart failure (HF) patients. Reduced free triiodothyronine (fT3) plasma level is associated with amore
severe disease and prognosis. The aim of this study was to evaluate the relationship between low fT3 plasma
level and reduced exercise capacity in chronic HF, and to determine the inﬂuence of a low T3 status in subsets
of patients with different functional impairment.
Methods and results: 240 HF patients (79% males; age 62±12 years, mean±standard deviation; left
ventricular ejection fraction, EF, 30±9%) underwent a CPT, clinical and neurohormonal characterization
(assay for plasma brain natriuretic peptide, BNP, norepinephrine, aldosterone, renin activity, fT3, free T4,
thyroid-stimulating hormone). At multivariate analysis in the whole population, age, gender and BNP level
were independently associated with peak VO2, whereas in patients with severe functional impairment (peak
VO2b14 ml/min/kg) fT3 resulted independently related to peak VO2, together with gender and BNP. When
patients with peak VO2b14 ml/min/kg were divided according to fT3 levels, patients with low T3 syndrome
showed reduced exercise capacity and worse ventilatory efﬁciency.
Conclusions: BNP and fT3 are independently associated with exercise capacity in severely compromised
HF patients.
© 2010 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Exercise intolerance is a hallmark of heart failure [1]. Cardiopul-
monary exercise testing (CPT) has beenwidely used in the assessment
of heart failure (HF), allowing an objective assessment of exercise
capacity, ventilatory response, clinical severity, and prognosis [1–3].
During exercise, oxygen uptake (VO2) directly correlates with cardiac
output. An inadequate cardiac output reserve is the primary
determinant of the impairment in aerobic capacity in asymptomatic
or mildly symptomatic HF patients [4]. However, when HF worsens,
several neurohormonal systems are activated, with a predominance of
sympathetic, renin–angiotensin–aldosterone systems [5], causing
downregulation/desensitization of beta-adrenergic receptors and
determining a decreased skeletal muscle vasodilation in response to
exercise: these mechanisms appear to be critical determinants of
decreased peak VO2 in moderate to severe HF [6].
As part of this complex neurohormonal response to cardiac
dysfunction, an altered thyroid hormone metabolism, i.e. the “lowar Medicine, Fondazione G.
. Tel.: +39 050 3152191; fax:
Ltd. All rights reserved.triiodothyronine (T3) syndrome”, has been reported in approximately
30% of patients with advanced HF and its presence is an independent
predictor of death [7–11]. This is characterized by low circulating
levels of the biologically active form of T3, in the presence of a normal
level of thyrotropin (thyroid-stimulating hormone [TSH]) and of the
pro-hormone thyroxin (T4), associated with abnormal peripheral
conversion of T4 to T3 [12,13].
The pathophysiological role of progressive decrease of T3 in HF has
not yet been completely established [14], but the cardiovascular
system is a principal target of the thyroid hormone, acting on heart
function and trophism, vascular tone [15–17] as well as on the skeletal
muscle system [18].
The possible role of the altered thyroid proﬁle on reduced
functional capacity in HF patients, as assessed by CPT, was examined
in only one previous study that reported a positive correlation
between total T3 levels and peak VO2 [19]. However, the number of
patients examined was small and neither free fractions of thyroid
hormones nor the other neurohormonal axes were considered.
The aim of this studywas to evaluate the relationship between free
T3 (fT3) and reduced exercise capacity in a larger HF population, who
underwent a comprehensive clinical and neurohormonal evaluation.
Moreover, we aimed to determine the inﬂuence of low T3 status in
subsets of patients with different functional impairment (dividing
Table 1
Patient characteristics.
Variable All patients
(n=240)
Peak VO2N14
(n=84)
Peak VO2b14
(n=156)
Age, years 62±12 54±13 66±10⁎
Gender, M/F, n 190/50 78/6 112/44⁎
Body mass index, kg/m2 27±4 26±8 27±5
Hypertension, n (%) 112 (47) 38 (45) 73 (48)
Diabetes, n (%) 74 (31) 12 (14) 61 (39)⁎
Dyslipidemia, n (%) 89 (37) 35 (42) 53 (35)
Ischaemic etiology, n (%) 97 (49) 26 (31) 70 (45)⁎
EF, % 30±9 35±9 31±8⁎
LVEDD, mm 62.4±7.6 62±8 63±7
LVEDV, mL 225±73 211±80 231±70
NYHA class (I/II/III), n 37/125/78 38/46/0 8/91/57⁎
ECrCl, ml/min 82±32 93±25 76±34⁎
TSH, μIU/mL 1.54
(0.98–2.45)
1.41
(0.94–2.23)
1.69
(0.98–2.50)
fT3, ng/L 2.43±0.42 2.56±0.40 2.3±0.41⁎
fT4, ng/L 12.22±2.84 11.71±2.67 12.4±2.91⁎
Norepinephrine, ng/L 531 (352–737) 427
(277–588)
600
(418–805)⁎
Plasma renin activity,
ng/L/h
1.58 (0.45–4.6) 1.17
(0.53–2.58)
1.69
(0.36–5.16)
Aldosterone, ng/L 140 (88–207) 132 (86–205) 145 (89–226)
BNP, ng/L 147 (43–348) 46 (23–145) 229 (86–516)⁎
Medications
Furosemide, n (%) 194 (80) 57 (68) 137 (89)⁎
Beta-blocker, n (%) 202 (84) 75 (89) 113 (72)
ACEi/ARBs, n (%) 207 (86) 82 (98) 125 (80)
Spironolactone, n (%) 144 (60) 19 (22) 125 (80)⁎
Device therapy (ICD/CRT),
n (%)
29 (12)/38 (16) 6 (7)/8 (10) 23 (15)/30 (19)
Values are expressed as mean±standard deviation for normally distributed variables,
and as median (25th–75th percentile) for non-normally distributed variables;
percentage and number of cases are presented for binary variables. Diabetes,
hypertension and dyslipidemia were considered positive if a patient had a
documented history or was currently on antidiabetic, antihyertensive or lipid-
lowering drug treatment, respectively.
AF=Atrial ﬁbrillation; EF=left ventricular ejection fraction; LVEDD=left ventricular end-
diastolicdiameter; LVEDV=left ventricular enddiastolic volume;NYHA in=NewYorkHeart
Association functional class; ECrCl=estimated creatinine clearance by Cockroft–Gault
formula; TSH=thyroid stimulating hormone; fT3=free triiodothyronine; fT4=free
thyroxine; BNP=brain natriuretic peptide; ACEi=angiotensinogen converting enzyme
inhibitors; ARBs=angiotensin receptor blockers.
⁎ pb0.05 vs patients with peak VO2N14.
Table 2
Cardiopulmonary test ﬁndings.
Variable All patients
(n=240)
Peak VO2N14
(n=84)
Peak VO2b14
(n=156)
Rest HR 72±13 71±16 73±12
Rest BP 107±20 110±23 105±21
Rest VO2, ml/min/kg 2.44±0.94 2.56±1.04 2.38±0.89
Rest VO2, L/min 0.19±0.7 0.20±0.06 0.18±0.08⁎
Peak HR, bpm 121±25 134±20 113±26⁎
Peak SBP, mmHg 158±28 170±25 151±27⁎
Peak VO2, L/min 0.97±0.40 1.37±0.34 0.74±0.23⁎
Peak VO2, ml/min/kg 12.5±4.5 17.4±3.2 9.86±2.37⁎
Peak VO2,% predicted 45±15 58±13 38±10⁎
Peak oxygen pulse, mL/beat 8.0±3.0 10.4±2.8 6.7±2.2⁎
Circulatory power,
mmHg ml/min/kg
2028±925 2985±755 1508±492⁎
Peak work rate, W 70±35 114±29 63±21⁎
BWi work rate, W/kg 1.04±0.39 1.43±0.31 0.84±0.24⁎
Peak RPP, bpm mmHg 19,000±5700 22,880±5007 17,166±5085
VE/VCO2 slope 37±10 32±8 40±10⁎
Peak RER 1.1±0.1 1.13±0.09 1.07±0.13⁎
Values are expressed as mean±standard deviation.
BP=blood pressure; BWi=Body weight-indexed HR=heart rate; RER=respiratory
exchange ratio RPP=rate pressure product; VE/VCO2 slope=regression slope relating
minute ventilation to carbon dioxide output; VO2=oxygen uptake.
⁎ pb0.05 vs patients with peak VO2N14.
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determinants of exercise intolerance, in asymptomatic/mildly symp-
tomatic patients (i.e. a reduced cardiac output reserve) and in
moderate/severe chronic HF patients (where abnormal “peripheral”
mechanisms play a greater role).
2. Methods
From January 2005 and December 2007 we evaluated 407 consecutive patients with
systolic HF (b50% left ventricular ejection fraction, EF; NewYork Heart Association, NYHA,
functional classiﬁcations I–III), referred to our Cardiovascular Medicine Division for HF
management. Of the 407 patients 4 were excluded because of overt primary
hypothyroidism [20] (TSHN10 mIU/mL and free T4, fT4b7 ng/L), 5 patients because of
hyperthyroidism [21] (free T3, fT3N4.2 ng/L and fT4N18.5 ng/L with undetectable TSH
level); 57 patients were excluded because of concomitant treatment with amiodarone, L-
T4 or T3 (n=57), 7 patients because of advanced renal impairment (i.e. estimated
creatinine clearance, ECrClb25 ml/min, estimated by the Cockroft–Gault formula), 3
patients for severe pulmonary or systemic disease and 91 patients were not able to
perform a valid CPT. Ultimately, 240 patients were enrolled.
All patients underwent a clinical, humoral and echocardiographic evaluation,
according to the recommendations of the American Society of Echocardiography
[22], CPT, thyroid function proﬁle and assay of plasma BNP, catecholamines, renin
activity (PRA) and aldosterone as described elsewhere [23,24]. All patients were
on stable, optimal pharmacological and device treatment.
The study was approved by the institutional Ethics Review Committee, and
conformed to the principles outlined in the Declaration of Helsinki; all patients gave
their informed consent.2.1. Neurohormonal and thyroid evaluation
Blood samples were withdrawn from an antecubital vein after a 20-min period
of supine rest between 8 and 9 a.m., after overnight fasting. The methods employed
for the assay of plasma BNP, catecholamines, renin activity (PRA) and aldosterone
are described elsewhere [23,24]. During the same morning fT3, fT4, and TSH were all
measured by a completely automated AIA 600 system (Tosho Corporation). The
reference intervals for our laboratory were as follows: fT3, 2.1 to 4.2 ng/L (i.e. 3.2 to
6.5 pmol/L); fT4, 7.1 to 18.5 pg/ml (i.e. 9.2 to 24 pmol/L); and TSH, 0.3 to 3.8 mIU/L.
2.2. Cardiopulmonary exercise testing
A CPT was performed by exercise on a bicycle ergometer using a step protocol with
increments of 10 W/min. We measured VO2, CO2 production, and minute ventilation
by means of breath-to-breath gas analysis (Vmax, Sensormedics, Conshohocken,
Pennsylvania). Peak oxygen consumption (peak VO2) (the highest value at end-
exercise, as 20-s average) and ventilatory efﬁciency on exercise (slope of the
ventilation vs VCO2 relation in its linear part) were determined. We then chose the
peak VO2 cut-off of 14 ml/min/kg, whose prognostic value is well established [25], to
test the inﬂuence of several pathophysiological markers on exercise capacity at
different stages of functional impairment.
2.3. Statistical analysis
Statistical analysis was performed using SPSS version 13.0. Data is expressed as
mean±standard deviation for variables with Gaussian distribution and as median,
25th–75th percentile for variables with log-normal distribution. Groups were
compared for categorical data or frequency of events using the chi-squared test and
for continuous variables using the Student's t test or the Mann–Whitney U test, as
appropriate (all tests were 2-sided). Log-transformed values of original data were used
in parametric and regression statistical analyses for continuous variables (such as BNP),
known to share a log-normal distribution.
Linear regression analysis was performed to assess the relationship between
indices of exercise capacity and other variables. A multiple linear regression model,
which included all variables found to be statistically signiﬁcant at univariate linear
regression (Pb0.05), was also used to tease out the relationship between the different
parameters and exercise capacity.
The diagnostic accuracy of BNP and fT3 in identifying patients with peak VO2 below
14ml/min/kg was quantiﬁed in terms of area under the ROC (Receiver Operating
Characteristic) curves (AUC). ROC curve analysis provided optimum cut-off values of BNP
and fT3 concentration (at the point of ROC curve corresponding to maximal sum of
speciﬁcity and sensitivity), as well as corresponding sensitivity and speciﬁcity.
3. Results
Clinical, humoral, and echocardiographic parameters as well as
level of neurohormones, thyroid hormones and TSH are summa-
rized in Table 1. CPT ﬁndings are summarized in Table 2.
Table 3
Univariate and multivariate predictors of peak VO2.
Variable Univariate
beta coefﬁcient
P value Multivariate
beta coefﬁcient
P value
Age 0.51 0.0001 −0.407 0.0001
Sex 0.0001 0.327 0.0001
BMI NS
ECrCl 0.32 0.0001 NS
Haemoglobin 0.38 0.0001 NS
EF 0.26 0.0001 NS
fT3 0.24 0.0001 NS
PRA NS
Aldosterone NS
Norepinephrine −0.301 0.0001 NS
BNP −0.48 0.0001 −0.267 0.0001
BMI: body mass index; ECrCl: estimated creatinine clearance by Cockroft–Gault
formula; EF: ejection fraction; fT3: free triiodothyronine; PRA: plasma renin activity;
BNP: brain natriuretic peptide. All variables found to be statistically signiﬁcant at
univariate linear regression (Pb0.05) were included into the multiple linear
regression model.
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pb0.001) with EF (r=0.26), fT3 (r=0.24), ECrCl (r=0.32), haemo-
globin (r=0.38), and inversely correlated with age (r=−0.51), BNP
(r=−0.48) and norepinephrine level (r=−0.301). At multivariate
analysis only age, gender, BNP level (all pb0.0001) were indepen-
dently associated with peak VO2 (Table 3) (R2 0.54 for the total
model).
Patients were then stratiﬁed according to functional capacity. In the
84 patients with peak VO2N14 ml/min/kg, peak VO2 showed a positive
relation with EF (r=0.265, p=0.015), and a negative relation with age
(r=−0.422, pb0.001), BNP (r=−0.255, p=0.019) and norepineph-
rine level (r=−0.310, p=0.005). At multivariate analysis only age
(pb0.001), gender (p=0.015), and EF (p=0.027) were independently
related to peak VO2 (Table 4) (R2 0.32 for the totalmodel). On the other
hand, in the 156 patients with peak VO2b14 ml/min/kg, peak VO2
correlated with estimated ECrCl (r=0.273, p=0.001), haemoglobin
(r=0.244, p=0.005), fT3 (r=0.313, pb0.001) and inversely with age
(r=−0.267, pb0.001), BNP (r=−0.209, p=0.011) (Fig. 1).
At multivariate analysis only gender (pb0.0001), fT3 (p=0.003),
and BNP level (p=0.046) were independently related to peak VO2
(Table 4) (R2 0.25 for the total model).
3.1. Exercise capacity according to the presence of low T3 syndrome in
patients with severely compromised functional capacity (i.e. patients
with peak VO2b14 ml/min/kg)
Forty-six patients (30%) of the group of patients with peak
VO2b14 ml/min/kg had a low T3’ status, i.e. fT3 below the lowerTable 4
Univariate and multivariate predictors of peak VO2 in patients with peak VO2 N or b14 ml/
Peak VO2N14 (n=84)
Univariate,
beta coefﬁcient
P Multivariate,
beta coefﬁcient
P
Age, years −0.422 0.0001 −0.405 0
Sex 0.0001 −0.244 0
Creatinine NS
ECrCl: NS
Haemoglobin NS
PRA
Aldosterone NS
Norepinephrine −0.310 0.005 N
LVEF 0.265 0.015 0.262 0
fT3 NS
BNP −0.255 0.019 N
ECrCl: estimated creatinine clearance by Cockroft–Gault formula; PRA: plasma renin activity
peptide. All variables found to be statistically signiﬁcant at univariate linear regression (Pblimit of the reference interval (i.e. b2.1 ng/L) associated with normal
level of TSH and fT4. No difference was found between the two
groups of patients with low T3 and normal thyroid proﬁle with
regard to age (67.4±12 vs 65.2±9.5), gender (69.6% males vs
73.4%), NYHA class (2.6±0.7 vs 2.4±0.6), BMI (26.4±4.3 kg/m2 vs
27.3±4.8 kg/m2), EF (30.37%±8.6 vs 30.65%±8.4), levels of BNP
[250 (112–676) ng/L vs 214 (226–477) ng/L], aldosterone [150 (79–
222) ng/L vs 142 (92–226) ng/L], PRA [1.58 (0.3–6.1) ng/L/h vs 1.69
(0.4–5.1) ng/L/h] and norepinephrine [602 (450–816) ng/L vs 582
(364–802) ng/L]. As compared to patients with normal hormonal
pattern, thosewith low fT3 serum levelshad lowerECrCl (64±34ml/min
vs81±33ml/min,p=0.005)andhaemoglobin (13.1±1.6 g/dl vs13.9±
1.4 g/dl, p=0.004).
As far as exercise capacity is concerned,patientswith lowT3syndrome
reached a lower workload (54±20W vs 67±20W pb0.001), even if
corrected for body weight (0.76±0.26W/kg vs 0.87±0.23W/kg vs
p=0.012), showed worse ventilatory efﬁciency expressed as a higher
VE/VCO2 slope (43±10 vs 39±9, p=0.027) and reduced exercise
capacity as expressed by peak VO2 (9.0±2ml/min/kg vs 10.2±2ml/
min/kg p=0.012). There were no differences in basal oxygen consump-
tion (0.18±0.7 ml/min/kgvs0.18±0.08 ml/min/kg), circulatory power
(1424±572mmHgml/min/kg vs 1543±453mmHgml/min/kg), ox-
ygen pulse at peak exercise (6.2±2.3 mL/beat vs 7.0±2.2 mL/beat,
p=0.068), peak heart rate (108±25 bpm vs 115.7±25 bpm).
3.2. Diagnostic accuracy of fT3 and BNP assays in identifying reduced
functional capacity among patients complaining symptoms
Atmultivariate analysis in symptomatic patients (i.e. NYHA classes
II–III, n=203), fT3 and BNP were independently related to peak VO2
(P=0.003), together with age and gender. ROC curve analysis
indicated the ability of BNP and fT3 to identify patients with reduced
functional capacity, i.e. peak VO2b14 ml/min/kg, (BNP: optimum cut-
point 264 ng/L, sensitivity 50%, speciﬁcity 89%, AUC 0.707, 95% CI
0.674–0.799; fT3: optimum cut-point 2.1 ng/L, sensitivity 36%,
speciﬁcity of 93%, AUC 0.660, 95% CI 0.590–0.725, respectively; both
BNP and fT3: AUC 0.770, 95% CI 0.706–0.827). The percentage of
patients with peak VO2b14 ml/min/kgwas highest among those with
both low fT3 and BNP above the cut-off value, as shown in Fig. 2.
4. Discussion
This study conﬁrms the association of neurohormonal activation
and exercise intolerance, as expressed by peak VO2, particularly in
those with peak VO2b14 ml/min/kg. Furthermore, in this subset of
patients, among all neurohormones examined, fT3 resulted indepen-
dently related to peak VO2, together with BNP.min/kg.
Peak VO2b14 (n=156)
Univariate,
beta coefﬁcient
P Multivariate,
beta coefﬁcient
P
.0001 −0.267 0.001 NS
.015∙ 0.011 −0.304 0.0001
NS
0.273 0.001 NS
0.244 0.005 NS
S
.027 NS
0.313 0.001 0.252 0.003
S 0.209 0.011 −0.181 0.046
; EF: left ventricular ejection fraction; fT3: free triiodothyronine; BNP: brain natriuretic
0.05) were included into the multiple linear regression model.
Fig. 1. Left panel: correlation between BNP and peak VO2; right panel: correlation between fT3 and peak VO2. Dotted lines represent 95% conﬁdence limits for slope of
regression line.
Fig. 2. Percentages of patients in NYHA class II/III with peak VO2b14 ml/min/kg,
according to fT3 and BNP cut-points, by Receiver Operating Characteristic analysis
(low fT3/high BNP: 97%; low fT3/low BNP: 87%; high fT3/high BNP: 79%; high fT3/low
BNP: 54%).
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limitation in patients with severe functional impairment may have a
multifactorial origin: in particular, besides a decreased cardiac
output reserve, abnormal peripheral mechanisms, inﬂuenced by the
neuro-hormonal regulatory system, may play a crucial role. It is
important to highlight that among all indices of the neurohormonal
axes studied (including the adrenergic and renin–angiotensin–
aldosterone systems), BNP and biologically active thyroid hormone
T3 resulted independently related to functional capacity in this
subset of patients. This data conﬁrms the close relationship between
exercise tolerance and B-type natriuretic peptide levels previously
shown in HF patients [26–28], but also indicate the existence of an
association between thyroid function and exercise capacity, whose
pathophysiologic meaning needs to be investigated.
The mechanisms correlating BNP production and biological active
thyroid hormone expression with peak VO2 are likely different.
Ventricular cardiomyocyte stretching, ventricular ﬁbrosis, hypoxia,
and neurohormonal system activation are considered as main stimuli
for B-type natriuretic hormone production and secretion [23,29].
Therefore, the measurement of circulating BNP and its related-
peptides is now considered to be a useful clinical marker of
myocardial function and neuro-hormonal activation [30–32]. The
association between BNP and peak VO2 conﬁrms the relevance of
haemodynamic conditions [23,29,33] and overall neurohormonal
activation [24] in determining exercise capacity.
On the other hand, low T3 status is a frequent marker of systemic
involvement in HF characterized by multi-organ impairment [34] and
is associated with reduced peripheral conversion of the T4 pro-
hormone into the biological active form T3. As concerns HF, the
relation between low fT3 and reduced functional capacity could be
explained by thyroid hormonal inﬂuence at both cardiovascular and
peripheral level through different pathways: a) direct T3 effect on
trophism and function of cardiomyocytes, with a positive chrono-
tropic and inotropic effect [35]; b) modulatory action on sympathetic
outﬂow (15–16); c) T3 vessel-relaxing action on peripheral vascula-
ture; d) the effect on metabolism and function of skeletal muscles
[18]. These last two points warrant speciﬁc attention, owing to the
greater role of abnormal peripheral mechanisms, i.e. skeletal muscle
with impaired oxidative metabolism and increased lactate production
as documented in mild hypothyroidism [18] and decreased muscle
vasodilation, in determining exercise intolerance in moderate and
severe chronic HF [36]. However, despite a trend (though not
signiﬁcant) toward a lower oxygen pulse at peak exercise (stroke
volume at peak exercise times the artero-venous difference) inpatients with low T3 syndrome and peak VO2 below 14 ml/min/kg, no
other differences in parameters evaluating central hemodynamic,
such as the circulatory power, a surrogate of the cardiac power (i.e.
the product of cardiac output and central aortic pressure) and the
heart rate, were found. Therefore, the present data do not allow to
draw straightforward conclusions about the greater role of peripheral
factors vs central haemodynamics in reducing exercise capacity and
further studies speciﬁcally focused on this issue are needed.
These results are in accordance with the independent, additive
prognostic value of BNP and fT3 in HF [37] and suggest the interesting
potential role of synthetic L-T3 replacement as a novel therapeutic
approach to improve exercise capacity in HF patients [38].
Finally, the correlation shown among BNP, fT3 and peak VO2 and
in particular the ability of the combination of high BNP and low
normal T3 in identifying patients with peak VO2b14 ml/min/kg
conﬁrms the ability of their combined assay to improve the power of
risk stratiﬁcation.
157M. Fontana et al. / International Journal of Cardiology 154 (2012) 153–157Our study has several limitations. Emphasis on the described
association does not prove causality: the hypothesis as to whether
changes in thyroid hormone metabolism could contribute mechanis-
tically to impaired functional capacity still needs to be fully
determined. To avoid possible confounders, we did select patients
according to thyroid function, tomedications directly affecting thyroid
function, and to presence of systemic comorbidities known to promote
a low T3 syndrome and a reduced functional capacity, independently
of cardiac function. For these reasons, the ﬁndings of the present study
cannot be generalized to unselected populations with HF.
In conclusion, low fT3 status is independently associated with
functional capacity in severe HF. Both BNP and thyroid hormone
level are related to exercise capacity in severely compromised HF
patients.
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